FDA approves Roche/Abbvie's Venclexta and Gazyva to combine treatments for CLL or SLL
-
Last Update: 2020-06-09
-
Source: Internet
-
Author: User
Search more information of high quality chemicals, good prices and reliable suppliers, visit
www.echemi.com
recently, the United StatesThe FDA(http://approved Roche/AbbVie's Venclexta and Gazyva as a first-line therapy for first-stage treatment of patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL)The approval is based on research data from the Phase 3 CLL14
trial(http://, which show that the combination therapy can reduce the risk of disease deterioration or death by 67% compared to Gazyva plus benzodiazepine (current standard of care) and significantly improve the progression-free survival of patientsIn the CLL14 clinical trial, patients received a 12-month course of treatment, and most patients remained untreated after two yearsVenetoclaxVenetoclax is a highly specific BCL-2 inhibitor and the first FDA-approved treatment for BCL-2BCL-2 plays an important role in apoptosis, and Venetoclax restores the apoptosis process of cancer cells by inhibiting BCL-2Venetoclax can target CD20 antigens expressed on the surface of specific B cells, directly attacking malignant B cells, or by regulating their own immune systems to fight cancerBut as recently as March, thedrug(http:// suffered a serious setback in its development in the field of multiple myelomaFirst, the deaths of subjects prompted U.Sregulators to halt recruitment programs for all Venclexta myeloma trialsin addition,, a combination of Venclexta, Takeda protease inhibitors Velcade and dexamethasone may double the patient's relative risk of death compared to placebo
This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only.
This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of
the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed
description of the concern or complaint, to
service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content
will be removed immediately.
